Elanco Animal Health Inc

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elanco Animal Health reports mixed 2022 results, eyes innovation growth

Elanco Animal Health's 2022 performance showed revenue decline but EPS growth, with a focus on innovation and portfolio strength for future growth.
The company aims to address challenges like competitive pressures and interest expenses while leveraging opportunities in product launches and margin improvement.
Financial projections include a net leverage ratio target for 2023, with plans for debt reduction and enhanced cash flow generation in the coming years.
Elanco's strategic focus on OTC parasiticides, innovation, and operational efficiency positions it well for sustained growth and market differentiation.

Elanco Animal Health reports Q1 growth and strategic outlook

Elanco Animal Health's Q1 2023 performance showcased revenue growth, strategic advancements, and improved cash flow generation, supported by successful ERP system integration benefits.
Despite challenges related to free cash flow, inventory discrepancies, and regulatory discussions, the company remains focused on optimizing working capital and enhancing financial metrics.
Opportunities lie in debt repayment, maintaining pricing benefits, upcoming product launches, and returning to growth in the second half of 2023, underpinned by global macro trends.
Elanco's strengths in market positioning, innovation progress, and strategic outlook for 2024 position the company for sustained growth and operational excellence in the animal health sector.

Elanco Animal Health surpasses Q2 targets, eyes global market growth

Elanco Animal Health exceeded Q2 targets, focusing on innovation and market expansion. While facing challenges in certain segments, the company is optimistic about future growth opportunities through differentiated products and global market strengths.

Elanco Animal Health excels in Q3, eyes sustained growth in 2024

Elanco Animal Health delivered a strong Q3 performance, emphasizing innovation and growth in international segments. While facing challenges in U.S. Pet Health and Farm Animal generics, the company is focused on driving sustainable growth through margin expansion and new product launches. Opportunities lie in upcoming blockbuster product launches and pricing strategies for 2024.

Elanco Animal Health reports growth in Q4 2023 earnings

Elanco Animal Health's Q4 2023 performance showed revenue growth driven by innovation and Farm Animal business strength.
Strategic restructuring aims to enhance efficiency and focus on pet health, while challenges include competitive pressures and margin headwinds.
Opportunities lie in continued growth, innovation, debt reduction, and commitment to new product sales targets.
Overall, Elanco remains confident in its position and ability to navigate market challenges.

Elanco Animal Health surpasses Q1 expectations, eyes revenue growth

Elanco Animal Health's Q1 2024 performance exceeded expectations, driven by strong Pet Health and Farm Animal segment growth, alongside improved cash flow and late-stage pipeline progress.
Despite challenges like product manufacturing issues and market queries, Elanco remains focused on innovation, market positioning, and executing its value agenda.
The company is poised for revenue growth, with positive outlooks for late-stage products and opportunities to capitalize on market demand and competitive strategies.
Elanco's strategic approach to product launches, market readiness, and portfolio expansion positions it well for future growth and market leadership.

Elanco Animal Health reports strong Q3 performance and growth outlook

Elanco Animal Health's Q3 performance reflects growth in key segments and products, with a focus on debt reduction and strategic investments.
The company faces challenges in competitive markets and supply chain transitions but is poised for growth through new product launches and market adoption.
Opportunities lie in expanding product reach, driving innovation sales, and navigating pricing trends to achieve mid-single-digit growth in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elanco stock surged Wednesday after the pet drugmaker beat first quarter expectations and hiked its profit guidance for the year.

Elanco Makes A Bullish Move On Its First Quarter Beat; Are Pet Health Stocks Forging A Comeback?

First Quarter 2024 Financial Results Revenue of $1,205 million Reported Net income of $32 million, Adjusted Net income of $167 million Adjusted EBITDA of $294 million, or 24.4% of Revenue Reported EPS of $0.06, Adjusted EPS of $0.34 Net leverage ratio of 6.1x Adjusted EBITDA Year over year growth rates are meaningfully impacted by a shift in customer purchasing related to the ERP Blackout in 2023, with an estimated $90 to $110 million of revenue shift from the second quarter of 2023 into the first quarter of 2023 Updating full year 2024 financial guidance to reflect first quarter outperformance offset by expected unfavorable impact of foreign exchange rates: Revenue of $4,460 to $4,515 million, constant currency growth improves to 2% to 3% Reported Net Loss of $(3) to $(45) million; Reported EPS of $(0.01) to $(0.09) Adjusted EBITDA of $960 to $1,000 million; Adjusted EPS of $0.88 to $0.96 GREENFIELD, Ind. , May 8, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the first quarter of 2024, provided guidance for the second quarter of 2024, and updated guidance for the full year 2024.

Elanco Animal Health Reports First Quarter 2024 Results

Beyond analysts' top -and-bottom-line estimates for Elanco Animal Health (ELAN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Countdown to Elanco Animal Health (ELAN) Q1 Earnings: Wall Street Forecasts for Key Metrics

GREENFIELD, Ind. , April 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024.

Elanco Confirms Date and Conference Call for First Quarter 2024 Financial Results Announcement

New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind. , April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members.

Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors

Investment firm Ancora Holdings has reached an agreement with Elanco Animal Health to add two of its director candidates to the company's board, Bloomberg News reported late on Sunday, citing people with knowledge of the matter.

Activist investor Ancora secures two Elanco board seats, Bloomberg News reports

GREENFIELD, Ind. , March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary.

Elanco Appoints Shiv O'Neill as General Counsel and Corporate Secretary

Ancora Nominates Director Candidates Despite Elanco's Meaningful Operational Progress and Good Faith Engagement with the Investor GREENFIELD, Ind. , Feb. 29, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today issued the following statement in response to the submission of four nominees to the Company's Board of Directors by Ancora Holdings Group, LLC ("Ancora"): The execution of Elanco's Innovation, Portfolio and Productivity strategy, led by CEO Jeff Simmons, is working.

Elanco Animal Health is Executing on Plan to Deliver for Shareholders

CLEVELAND--(BUSINESS WIRE)--Ancora Holdings Group, LLC (together with its affiliates, “Ancora” or “we”), which owns approximately 3% of the outstanding common stock of Elanco Animal Health Incorporated (NYSE: ELAN) (“Elanco” or the “Company”), today issued the below statement regarding its nomination of four highly qualified, independent candidates for election to the Company's Board of Directors (the “Board”) at the 2024 Annual Meeting of Shareholders (the “Annual Meeting”). Ancora has also re.

Ancora Nominates Four Highly Qualified, Independent Director Candidates and Urges Orderly CEO Succession at Elanco Animal Health

Elanco Animal Health (ELAN) Q4 2023 Earnings Call Transcript

The headline numbers for Elanco Animal Health Incorporated (ELAN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Elanco Animal Health Incorporated (ELAN) Q4 Earnings

Fourth Quarter 2023 Financial Results: Revenue of $1,035 million Reported Net Loss of $141 million, Adjusted Net Income of $39 million Adjusted EBITDA of $165 million or 15.9% of Revenue Reported EPS of $(0.29), Adjusted EPS of $0.08  Net leverage ratio of 5.6x Adjusted EBITDA Full Year 2023 Financial Results: Revenue of $4,417 million Reported Net Loss of $1,231 million, Adjusted Net Income of $439 million Adjusted EBITDA of $979 million or 22.2% of Revenue Reported EPS of $(2.50), Adjusted EPS of $0.89  Full Year 2024 Guidance: Revenue of $4,450 to $4,540 million Reported Net Loss of $17 to $62 million, Adjusted EBITDA of $960 to $1,010 million Reported EPS of $(0.12) to $(0.03), Adjusted EPS of $0.87 to $0.95 Guidance includes full year contribution of the company's aqua business and does not consider contribution from expected launches of three blockbuster-potential products Announced strategic restructuring impacting approximately 420 personnel, resulting in a charge to 2024 reported results of $50 to $55 million and generating approximately $30 to $35 million in annualized savings, which the company plans to reinvest in more significant value creation opportunities GREENFIELD, Ind. , Feb. 26, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2023 and provided initial guidance both for the first quarter and full year 2024.

Elanco Animal Health Reports Fourth Quarter and Full Year 2023 Results

GREENFIELD, Ind. , Feb. 22, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences.

Elanco to Participate in Upcoming Investor Conferences

Get a deeper insight into the potential performance of Elanco Animal Health Incorporated (ELAN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Elanco Animal Health Incorporated (ELAN) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Elanco Animal Health Incorporated (ELAN) to Report a Decline in Earnings: What to Look Out for

SARATOGA, Calif. , Feb. 8, 2024 /PRNewswire/ -- Cattler ( www.cattler.farm ) announces the launch of its interface with Elanco Animal Health Incorporated (NYSE: ELAN), as part of the agreement reached September 2023, to provide data collaboration for customers participating in Elanco Knowledge Solutions (EKS) services that include (but are not limited to) Benchmark TM and Experior TM Data Services.

Beef 'agtech' company Cattler launches interface with Elanco for its Benchmark program

GREENFIELD, Ind. , Feb. 8, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2023 financial results on Monday, February 26, 2024.

Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2023 Financial Results Announcement

Merck

Elanco Animal Health Inc has announced the sale of its aqua business to Merck Animal Health for US$1.3 billion in a bid to refocus on other markets. This will enable Elanco to accelerate debt paydown by US$1.05 billion to US$1.1 billion, the company said on Monday, with the proceeds representing over seven times the estimated 2023 revenue of the hot and cold water species product firm.

Elanco Animal Health sells aqua business to Merck for $1.3 billion

Merck struck a deal to buy Elanco Animal Health's aqua business in a deal that expands the drugmaker's animal-health business.

Merck to Buy Elanco's Aqua Business for $1.3 Billion

Merck said on Monday it had agreed to buy Elanco Animal Health's aqua business for $1.3 billion in cash, to strengthen its portfolio of aquatic healthcare products.

Merck to buy Elanco Animal Health's aqua business for $1.3 bln

Elanco Animal Health Inc. ELAN, -0.41% said Monday it has agreed to sell its aqua business to Merck Animal Health MRK, +0.02% for $1.3 billion in cash. Greenfield, Ind.

Elanco Animal Health agrees to sell aqua business to Merck for $1.3 billion in cash

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN) for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing fac.

Merck Animal Health to Acquire Elanco's Aqua Business

Transaction reinforces Elanco's commitment to most significant value creation opportunities in pet health and livestock sustainability Enables company to accelerate debt paydown by $1.05B to $1.1B GREENFIELD, Ind. , Feb. 5, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement to sell its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 billion in cash, which represents approximately 7.4x the estimated 2023 revenue of the Elanco aqua business.

Elanco Announces Sale of Aqua Business for $1.3 Billion

Tonisity and Elanco to Expand Partnership into the Japanese Swine Market Greenfield, Indiana, Fort Collins, Colorado, Basel, Switzerland and Dublin, Ireland--(Newsfile Corp. - January 31, 2024) - Elanco Animal Health Incorporated ("Elanco") (NYSE: ELAN), a global leader in animal health, and Tonisity International Limited ("Tonisity"), an animal health and nutrition company based in Ireland, are pleased to announce that they have received the permission from the Japanese Ministry of Agriculture, Forestry and Fisheries ("MAFF") to import and sell Tonisity Px in the Japanese market. Having now obtained permission of MAFF to import Tonisity Px into Japan, Tonisity and Elanco are now positioned to immediately accelerate sales of Px into Japan, an important swine market in Asia.

Tonisity and Elanco Announce Receipt of Permission from the Japanese Government for Tonisity Px Import and Sales

Calling all Veterinarians and Pet Lovers - Take the "Defend Puppies. Defeat Parvo.

News for Elanco Animal Health Inc Stock (ELAN)